Blood test score may guide ovarian cancer treatment decisions

NCT ID NCT06660147

Completed Knowledge-focused Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a score called KELIM can predict how well ovarian cancer patients respond to maintenance treatment with PARP inhibitors after initial chemotherapy. Researchers will analyze data from 243 patients who took part in the PAOLA-1 trial. If KELIM proves useful, it could help doctors personalize treatment and avoid giving strong medications to those unlikely to benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If KELIM proves reliable, doctors could better match ovarian cancer patients to PARP inhibitor treatment, avoiding unnecessary side effects and focusing therapy on those most likely to benefit.
What could go wrong: This is a retrospective analysis of existing data, not a new treatment trial. The KELIM score may not prove accurate enough to change clinical practice, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

CHRU Besançon - Hôpital Jean Minjoz

Besançon, 25030, France
CHU Grenoble-Alpes - Site Nord (La Tronche)

Grenoble, 38043, France
CHU de Poitiers - Hôpital de la Milétrie

Poitiers, 86021, France
Centre Azuréen de Cancérologie

Mougins, 06250, France
Centre Eugène Marquis

Rennes, 35042, France
Centre François Baclesse

Caen, 14076, France
Centre Hospitalier Départemental de Vendée

La Roche-sur-Yon, 85925, France
Centre Hospitalier Princesse Grace

Monaco, 98012, Monaco
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Clinique Francheville

Périgueux, 24004, France
Clinique Pasteur

Toulouse, 31300, France
Groupe Hospitalier Diaconesses - Croix Saint-Simon

Paris, 75012, France
Gustave Roussy

Villejuif, 94805, France
HCL - Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Hôpital Cochin

Paris, 75014, France
Hôpital Européen Georges Pompidou

Paris, 75015, France
Hôpital Privé du Confluent

Nantes, France
ICL - Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54519, France
ICO - Centre René Gauducheau

Saint-Herblain, 44805, France
ICO Paul Papin

Angers, 49055, France
Institut Curie

Paris, 75248, France
Oncopole Claudius Regaud - IUCT Oncopole

Toulouse, 31059, France
Polyclinique Bordeaux Nord

Bordeaux, 33300, France
Sainte-Catherine Institut du Cancer Avignon-Provence

Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.